Form 4: Calidi CSO Granted 35,000 Stock Options

Calidi Biotherapeutics' Chief Scientific Officer, Antonio Fernandez Santidrian, was granted 35,000 incentive stock options at an exercise price of $1.58.

Summary

• Antonio Fernandez Santidrian, Chief Scientific Officer of Calidi Biotherapeutics, Inc. (CLDI), was granted 35,000 incentive stock options.
• The options were granted on September 3, 2025, under the Issuer's 2023 Equity Incentive Plan.
• The exercise price for these options is $1.58 per share, which was the closing price of the company's common stock on the grant date.
• The options have an expiration date of September 3, 2035.
• Vesting schedule dictates 25% of the options will vest on September 3, 2026 (the one-year anniversary of the grant date).
• The remaining 75% of the options will vest in 1/36th monthly installments on the last day of each monthly period thereafter, contingent on Mr. Santidrian's continued service to the Issuer.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a positive for aligning management incentives with shareholder interests and for executive retention, which is standard practice. It does not indicate any immediate operational or financial changes, but rather reinforces long-term strategic alignment.

Positives

• The grant of incentive stock options aligns the Chief Scientific Officer's financial interests with those of shareholders, encouraging long-term performance.
• Equity compensation is a standard tool for executive retention, helping to secure key talent like the Chief Scientific Officer.
• The options were granted at the closing price on the grant date, indicating a fair market valuation at the time of issuance.

Future Outlook

The vesting schedule for the granted options extends through monthly installments following the one-year anniversary of the grant date, contingent on the Chief Scientific Officer's continued service to the company.

Industry Context

The grant of stock options to a Chief Scientific Officer is a common and standard practice within the biotechnology and pharmaceutical industries. It serves as a key component of executive compensation packages, designed to attract, retain, and motivate high-level scientific and management talent by aligning their long-term financial incentives with company performance and shareholder value creation.

Comparison to Industry Standards

• The use of incentive stock options with a multi-year vesting schedule is a standard compensation mechanism in the biotechnology sector, comparable to practices at companies like Moderna, BioNTech, or Gilead Sciences, which frequently use equity to incentivize key scientific and executive personnel.
• The exercise price being equal to the closing price on the grant date is a common and transparent method for pricing options, consistent with industry best practices to avoid immediate in-the-money grants that could be perceived negatively.

Corporate Governance

Related Party Transactions

• The grant of 35,000 incentive stock options to Antonio Fernandez Santidrian, the Chief Scientific Officer, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from aligned management incentives for long-term value creation.
• Employees: Reinforces the company's commitment to equity-based compensation, potentially impacting morale and retention for other key personnel.

Next Steps

• Continued service of the Chief Scientific Officer to meet vesting conditions for the stock options.
• Future vesting events on September 3, 2026, and subsequent monthly installments.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to a key executive, which is a standard practice for executive compensation and retention. It does not contain information that would significantly alter the investment thesis for Calidi Biotherapeutics, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Calidi Biotherapeutics, CLDI, Stock Options, Executive Compensation, Equity Incentive Plan, Form 4, Biotechnology, Insider Transaction